http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110141664-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 |
| filingDate | 2019-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110141664-B |
| titleOfInvention | Pharmaceutical composition for treating acute myeloid leukemia |
| abstract | The invention relates to a pharmaceutical composition for treating leukemia, which comprises homoharringtonine and a Wee1 kinase inhibitor as active ingredients, wherein the weight ratio of homoharringtonine to the Wee1 kinase inhibitor is 1:10-10: 1. The pharmaceutical composition has remarkable curative effect on treating leukemia, particularly chronic myelogenous leukemia or acute myelogenous leukemia. The invention provides a brand new idea for developing a combined administration scheme for treating leukemia. |
| priorityDate | 2019-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 139.